Catabasis Pharma (CATB) Tops Q1 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall St futures mixed ahead of CPI, bank earnings; US-Iran tensions in focus
- SK Hynix’s record plunge drags down global chip stocks
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
- Goldman Sachs Upgrades NIO (NIO) to Buy
- IBM misses Q2 targets as mainframe and software sales disappoint
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
- YPF Energía Eléctrica S.A. files for proposed NYSE IPO
Catabasis Pharmaceuticals Reports First Quarter 2017 Financial Results and Reviews Business Progress
May 11, 2017 4:10 PM EDT-- Improvements Seen Across Functional Assessments in Boys Treated with Edasalonexent for 12 Weeks in Part B of the MoveDMD® Trial in Duchenne Muscular Dystrophy --
-- MoveDMD Trial Progressing, Part C Interim Results Expected in Q3 2017 --
-- Rare Disease Pipeline Programs Advancing in Cystic Fibrosis and Neurodegenerative Diseases --
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Catabasis Pharmaceuticals,... More
